MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation - Seite 2

Expected timeline for implementation of the Transaction

In view of the approval by the EGM, the Company will now start implementing the Transaction in accordance with the following expected timeline:

Key step	Date
First trading day on Euronext Brussels of the new Shares following the Share Consolidation (see also below)	November 14, 2023
Effective date of the Mandatory ADS Exchange	November 27, 2023
Admission to trading of the Shares on Nasdaq, and start of the Transition Period	November 27, 2023
End of the Transition Period and De-Listing	December 15, 2023

The Company will update the timeline throughout the implentation process, and inform its shareholders and other stakeholders accordingly. Furthermore, as the implementation process progresses, the Company intends to further communicate on each relevant step.

Details of the Share Consolidation

As first step of the Transaction, the Company will now start with implementing the approved Share Consolidation with respect to all of the Company's outstanding Shares by means of a 1-for-10 reverse stock split.

Simultaneous and automatic implementation of the Share Consolidation

Pursuant to the Share Consolidation, all existing Shares of the Company will be consolidated into a new and reduced number of Shares at the ratio of one (1) new Share (ISIN BE0974461940) for ten (10) existing Shares (ISIN BE0003844611).

The last trading day of the existing Shares (ISIN BE0003844611) on the regulated market of Euronext Brussels will be November 13, 2023. The first trading date of the new Shares (ISIN BE0974461940) on the regulated market of Euronext Brussels will be November 14, 2023.

The Share Consolidation will be carried out simultaneously for all outstanding Shares, so that after the completion of the Share Consolidation each new Share will represent the same fraction of the Company's share capital. All new Shares after the completion of the Share Consolidation will have the same rights and benefits, and will rank pari passu in all respects, including as to entitlements to dividends and other distributions. The Share Consolidation will not affect the form of the outstanding Shares (dematerialised or registered) and the outstanding registered and dematerialised Shares will be processed separately. The Share Consolidation will be implemented automatically, without the need for shareholders to take any steps whatsoever.